What the FDA labels say about taking them together
Digoxin and remibrutinib
Remibrutinib's FDA label of March 23, 2026 names digoxin in its drug interactions section; the digoxin labels PlainMeds reads (3) do not name remibrutinib. The remibrutinib label: “Monitor more frequently for adverse reactions when using RHAPSIDO with P-glycoprotein (P-gp) substrates where minimal concentration changes may lead to serious adverse reactions (e.g., digoxin).”
Check it at the source: the digoxin FDA label on DailyMed (effective December 5, 2024, Advanz Pharma (US) Corp.); the remibrutinib FDA label on DailyMed (effective March 23, 2026, Novartis Pharmaceuticals Corporation).
What does the digoxin label say about remibrutinib?
Digoxin's label (effective December 5, 2024) and its 2 other brand-application labels do not name remibrutinib in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (LANOXIN), Advanz Pharma (US) Corp., effective December 5, 2024 (SPL set d91e3646-4c63-4512-ab22-db39c085c4dc), via openFDA; the full label on DailyMed
What does the remibrutinib label say about digoxin?
Remibrutinib label, drug interactionsMonitor more frequently for adverse reactions when using RHAPSIDO with P-glycoprotein (P-gp) substrates where minimal concentration changes may lead to serious adverse reactions (e.g., digoxin).
Source: FDA drug label (RHAPSIDO), Novartis Pharmaceuticals Corporation, effective March 23, 2026 (SPL set e5e89bff-6ced-4165-acc5-fb13136b3a3d), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Digoxin | Remibrutinib | |
|---|---|---|
| Labeled for | Heart failure, Atrial fibrillation | Allergies |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.133 per tablet 125 mcg tablet | $72.46 per tablet 25 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once